[{"id":"778d6e97-aaea-4385-b9ac-14c267296d2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474324","created_at":"2026-03-28T01:42:37.705Z","updated_at":"2026-03-28T01:42:37.705Z","phase":"Phase 2","brief_title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","source_id_and_acronym":"NCT07474324","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2026-03-16"},{"id":"eebefa81-1645-4e61-b40b-7636aef12cd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012031","created_at":"2025-06-14T13:57:15.769Z","updated_at":"2025-06-14T13:57:15.769Z","phase":"Phase 1/2","brief_title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","source_id_and_acronym":"NCT07012031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ERBB3","pipe":" | ","alterations":" HER-2 overexpression","tags":["KRAS • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/06/2025","start_date":" 06/06/2025","primary_txt":" Primary completion: 06/14/2027","primary_completion_date":" 06/14/2027","study_txt":" Completion: 06/14/2027","study_completion_date":" 06/14/2027","last_update_posted":"2025-06-11"},{"id":"44d24989-a21f-4511-a498-f631f60a4181","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554109","created_at":"2021-01-18T17:29:18.298Z","updated_at":"2025-02-25T13:39:37.796Z","phase":"Phase 2","brief_title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine","source_id_and_acronym":"NCT03554109","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 02/09/2022","study_completion_date":" 02/09/2022","last_update_posted":"2025-02-21"},{"id":"2a50b5f1-093a-4091-9487-67d57ccd0fe8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990921","created_at":"2021-08-05T14:53:11.959Z","updated_at":"2025-02-25T13:53:55.184Z","phase":"Phase 2","brief_title":"Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer","source_id_and_acronym":"NCT04990921","lead_sponsor":"University of Louisville","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/02/2021","start_date":" 09/02/2021","primary_txt":" Primary completion: 07/01/2031","primary_completion_date":" 07/01/2031","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2025-02-20"},{"id":"3875d166-2701-445e-aa30-32ca8986f0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03092518","created_at":"2021-01-18T15:14:06.092Z","updated_at":"2025-02-25T14:01:14.625Z","phase":"Phase 2","brief_title":"Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology","source_id_and_acronym":"NCT03092518","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • mitomycin • Jelmyto (mitomycin urothelial gel)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/05/2017","start_date":" 06/05/2017","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-02-19"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"830f0798-1d87-4b27-be23-d2bdac97c17f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01649271","created_at":"2021-01-18T07:06:15.291Z","updated_at":"2025-02-25T15:25:12.158Z","phase":"Phase 1","brief_title":"Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.","source_id_and_acronym":"NCT01649271","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/23/2012","start_date":" 07/23/2012","primary_txt":" Primary completion: 06/23/2016","primary_completion_date":" 06/23/2016","study_txt":" Completion: 06/23/2016","study_completion_date":" 06/23/2016","last_update_posted":"2025-02-11"},{"id":"4e3eec72-a814-4c0e-9cb1-d5be450dc993","acronym":"BEAMION-Lung 1","url":"https://clinicaltrials.gov/study/NCT04886804","created_at":"2021-05-14T12:52:37.162Z","updated_at":"2025-02-25T15:35:04.451Z","phase":"Phase 1","brief_title":"Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)","source_id_and_acronym":"NCT04886804 - BEAMION-Lung 1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NRG1","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 mutation","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hernexeos (zongertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 554","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 01/28/2028","study_completion_date":" 01/28/2028","last_update_posted":"2025-02-10"},{"id":"75e429d1-288b-438c-890d-57227288a551","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436254","created_at":"2021-01-18T01:32:21.652Z","updated_at":"2025-02-25T16:35:57.454Z","phase":"Phase 1","brief_title":"Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer","source_id_and_acronym":"NCT00436254","lead_sponsor":"University of Washington","biomarkers":" HER-2 • MUC16","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AST-301 • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 10/01/2001","start_date":" 10/01/2001","primary_txt":" Primary completion: 03/01/2010","primary_completion_date":" 03/01/2010","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-06"},{"id":"f231b1ba-c963-4fcd-a957-1503f6a6f741","acronym":"SGNTUC 024","url":"https://clinicaltrials.gov/study/NCT04430738","created_at":"2021-01-18T21:20:17.873Z","updated_at":"2025-02-25T16:37:54.749Z","phase":"Phase 1/2","brief_title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","source_id_and_acronym":"NCT04430738 - SGNTUC 024","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"6a7e2afb-013b-43d3-b31e-6052a197be35","acronym":"met-HEReMYTA","url":"https://clinicaltrials.gov/study/NCT02488564","created_at":"2021-01-18T11:59:22.933Z","updated_at":"2025-02-25T16:58:50.319Z","phase":"Phase 2","brief_title":"A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02488564 - met-HEReMYTA","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • metformin • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 12/17/2014","start_date":" 12/17/2014","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 03/17/2020","study_completion_date":" 03/17/2020","last_update_posted":"2025-02-03"},{"id":"8a36dc46-7e94-43f5-8360-2cd36c81ca39","acronym":"","url":"https://clinicaltrials.gov/study/NCT04034251","created_at":"2021-01-18T19:47:54.419Z","updated_at":"2025-02-25T17:00:07.598Z","phase":"Phase 2","brief_title":"Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis","source_id_and_acronym":"NCT04034251","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 02/25/2023","primary_completion_date":" 02/25/2023","study_txt":" Completion: 09/05/2024","study_completion_date":" 09/05/2024","last_update_posted":"2025-02-03"},{"id":"6bcd23c9-26d4-4ce6-8abc-592de885dbb3","acronym":"TWINPEAK","url":"https://clinicaltrials.gov/study/NCT05482893","created_at":"2022-08-01T14:54:48.052Z","updated_at":"2025-02-25T16:18:00.073Z","phase":"Phase 1/2","brief_title":"Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)","source_id_and_acronym":"NCT05482893 - TWINPEAK","lead_sponsor":"Phanes Therapeutics","biomarkers":" CLDN18","pipe":" | ","alterations":" HER-2 overexpression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • spevatamig (PT886)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-01-31"},{"id":"f65dd733-9008-4681-bf13-626c30073cdc","acronym":"SAFIR 03","url":"https://clinicaltrials.gov/study/NCT05625087","created_at":"2022-11-22T15:59:03.927Z","updated_at":"2025-02-25T15:54:42.995Z","phase":"Phase 2","brief_title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","source_id_and_acronym":"NCT05625087 - SAFIR 03","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • triptorelin"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 10/19/2023","start_date":" 10/19/2023","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-01-30"},{"id":"7d906406-3512-4d2f-bf49-f76062d2546f","acronym":"MCC-20899","url":"https://clinicaltrials.gov/study/NCT04923542","created_at":"2021-06-11T18:56:15.461Z","updated_at":"2025-02-25T17:37:10.115Z","phase":"Phase 1/2","brief_title":"Stereotactic Radiation \u0026 Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases","source_id_and_acronym":"NCT04923542 - MCC-20899","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-01-29"},{"id":"d258ffb1-712c-47d0-9e3b-45ef523e42fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181333","created_at":"2021-01-18T20:23:20.534Z","updated_at":"2025-02-25T17:36:28.904Z","phase":"","brief_title":"Safety and Efficacy of Trastuzumab BS","source_id_and_acronym":"NCT04181333","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 08/09/2023","start_date":" 08/09/2023","primary_txt":" Primary completion: 02/14/2025","primary_completion_date":" 02/14/2025","study_txt":" Completion: 02/14/2025","study_completion_date":" 02/14/2025","last_update_posted":"2025-01-28"},{"id":"1467939e-4841-48a9-aba1-4c56c0ac9027","acronym":"","url":"https://clinicaltrials.gov/study/NCT03125928","created_at":"2021-01-18T15:24:05.399Z","updated_at":"2025-02-25T12:26:39.477Z","phase":"Phase 2","brief_title":"Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer","source_id_and_acronym":"NCT03125928","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • Perjeta (pertuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-01-10"},{"id":"3554ca16-61bd-4047-833c-b83d03ee0735","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038539","created_at":"2023-09-15T18:09:54.550Z","updated_at":"2025-02-25T13:55:34.751Z","phase":"Phase 3","brief_title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","source_id_and_acronym":"NCT06038539","lead_sponsor":"Biocon Biologics UK Ltd","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • Perjeta (pertuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 382","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2024-12-17"},{"id":"b8fdfff2-f67c-48fd-9e76-9ef9443b1f2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05480384","created_at":"2022-07-29T15:55:22.037Z","updated_at":"2025-02-25T15:00:32.371Z","phase":"Phase 2","brief_title":"Adjuvant Trastuzumab Deruxtecan (Enhertu) \u0026 Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus \u0026 Gastroesophageal Junction","source_id_and_acronym":"NCT05480384","lead_sponsor":"Brown University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-11-25"},{"id":"fcdaa581-7698-4699-bff1-a8e70321bccc","acronym":"DESTINY-CRC02","url":"https://clinicaltrials.gov/study/NCT04744831","created_at":"2021-02-09T13:53:02.487Z","updated_at":"2025-02-25T14:59:42.256Z","phase":"Phase 2","brief_title":"Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04744831 - DESTINY-CRC02","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • TMB • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 overexpression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type","tags":["EGFR • HER-2 • BRAF • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 overexpression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 10/08/2024","study_completion_date":" 10/08/2024","last_update_posted":"2024-11-19"},{"id":"a35ae63d-7bfa-40bf-b911-fec1b0dea308","acronym":"DECIPHER","url":"https://clinicaltrials.gov/study/NCT05965479","created_at":"2023-07-31T17:08:57.339Z","updated_at":"2025-02-25T15:01:01.413Z","phase":"Phase 2","brief_title":"Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","source_id_and_acronym":"NCT05965479 - DECIPHER","lead_sponsor":"University of Southampton","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/10/2024","start_date":" 04/10/2024","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-11-11"},{"id":"7b8a02fc-93ba-4510-a730-5331f3179340","acronym":"","url":"https://clinicaltrials.gov/study/NCT04147819","created_at":"2021-01-18T20:19:04.190Z","updated_at":"2025-02-25T17:11:00.786Z","phase":"Phase 1","brief_title":"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein","source_id_and_acronym":"NCT04147819","lead_sponsor":"Bayer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY2701439 • BAY2701438"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 09/26/2023","study_completion_date":" 09/26/2023","last_update_posted":"2024-09-27"},{"id":"03fa7b60-29a0-4a44-aa05-14a8b5df45eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02091141","created_at":"2021-01-17T17:15:36.027Z","updated_at":"2025-02-25T12:26:06.921Z","phase":"Phase 2","brief_title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02091141","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 673","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-07-23"},{"id":"0ee26aec-9472-428d-8a6d-1452f4bd5bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05283837","created_at":"2022-03-17T12:53:29.116Z","updated_at":"2025-02-25T13:54:17.342Z","phase":"Phase 3","brief_title":"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)","source_id_and_acronym":"NCT05283837","lead_sponsor":"Zydus Lifesciences Limited","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 268","initiation":"Initiation: 09/26/2022","start_date":" 09/26/2022","primary_txt":" Primary completion: 09/06/2023","primary_completion_date":" 09/06/2023","study_txt":" Completion: 09/06/2023","study_completion_date":" 09/06/2023","last_update_posted":"2024-07-18"}]